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Abstract Iron may be implicated in the generation of
oxidative stress by the catalyzing the Haber–Weiss or
Fenton reaction. On the other hand, oxidative stress has
been implicated in the pathogenesis of age-related macular
degeneration (AMD) and heme oxygenase-1 (HO-1),
encoded by the HMOX1 gene and heme oxygenase-2 (HO-
2), encoded by the HMOX2 gene are important markers of
iron-related oxidative stress and its consequences. There-
fore, variability of the HMOX1 and HMOX2 genes might
be implicated in the pathogenesis of AMD through the
modulation of the cellular reaction to oxidative stress. In
the present work, we investigated the association between
AMD and a G ? C transversion at the 19 position in the
HMOX1 gene (the 19G[C-HMOX1 polymorphism,
rs2071747) and a A ? G transition at the -42 ? 1444
position in the HMOX2 gene (the -42 ? 1444A[G-
HMOX2 polymorphism, rs2270363) and its modulation by
some environmental factors. 279 patients with AMD and
105 controls were recruited in this study and the poly-
morphisms were typed by restriction fragment length
polymorphism and allele-speciﬁc polymerase chain reac-
tion (PCR). We observed an association between the
occurrence of dry AMD and the G/A genotype of the
-42 ? 1444A[G-HMOX2 polymorphism (odds ratio
(OR) 2.72), whereas the G/G genotype reduced the risk of
dry AMD (OR 0.41). The G/C genotype and the C allele of
the 19 G[C-HMOX1 polymorphism and the G/G genotype
and the G allele of the -42 ? 1444A[G-HMOX2 poly-
morphism were associated with progression of AMD from
dry to wet form (OR 4.83, 5.20, 2.55, 1.69, respectively).
On the other hand, the G/G genotype and the G allele of the
19 G[C-HMOX1 polymorphism and the A/G genotype and
the A allele of the -42 ? 1444A[G-HMOX2 polymor-
phism protected against AMD progression (OR 0.19, 0.19,
0.34, 0.59, respectively). Therefore, the 19G[C-HMOX1
and the -42 ? 1444A[G-HMOX2 polymorphisms may be
associated with the occurrence and progression of AMD.
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Introduction
Age-related macular degeneration (AMD) is an eye disease
that results in a progressive and irreversible loss of central
vision and is considered as the primary cause of visual
impairment, including blindness in the elderly, in indus-
trialized countries [1, 2]. This disease affects the retinal
pigment epithelium (RPE), Bruch’s membrane (BM) and
choriocapillaries [3, 4]. The etiology of AMD is not fully
understood and it is likely underlined by a complex inter-
action between genetic and environmental factors [5]. The
latter are age, smoking, sex, Caucasian ethnicity, chronic
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cular diseases [6–9]. A number of epidemiological studies
has indicated AMD as an inherited disease, showing that
family members are at an increased risk [10–15].
Several studies on the molecular character of AMD
suggest an important role of oxidative stress in its
pathology. The retina in general, and macula in particular
are highly susceptible to oxidative stress because of ele-
vated oxygen pressure, high metabolic activity, prolonged
exposure to UV and blue light, presence of photosensi-
tizers and oxidative phagocytosis of photoreceptors. Also
iron overload in the retina may contribute to its oxidative
damage by the catalyzing Haber–Weiss and Fenton
reactions, producing reactive oxygen species (ROS)
[16, 17]. AMD may be exacerbated by retinal iron
overload and eyes with macular degeneration showed
elevated levels of iron in the RPE, BM and within drusen
[18]. Moreover, the concentration of retinal iron increases
with age [19].
Several enzymes are important in the formation and
reduction of iron-generated ROS. Heme oxygenase-1 (HO-
1), encoded by the HMOX1 gene and the closely related
heme oxygenase-2 (HO-2), encoded by the HMOX2 gene,
convert heme, a powerful pro-oxidant, to biliverdin, which
is then changed to bilirubin, a strong antioxidant, by the
enzyme biliverdin reductase. Because of this activity, HOs
may have an important role in oxidative stress-related
diseases, including AMD. HO-1 and HO-2 levels were
found to decrease with age in RPE cells from eyes with
evidence of neovascular AMD [20].
As HO-1 and HO-2 may be involved in AMD, the
variation in the sequence of their genes may also contribute
to this disease. Many studies conﬁrmed the association
between genetic variability and AMD [21–26]. In the
present work we investigated the association between a
G ? C transversion at the 19 position in the HMOX1 gene
(the 19G[C-HMOX1 polymorphism, rs2071747) and an
A ? G transition at the -42 ? 1444 position in the
HMOX2 gene (the -42 ? 1444A[G-HMOX2 polymor-
phism, rs2270363) and AMD. We also investigated the
modulation of such possible association by some clinical
and life-style factors. The 19 G[C-HMOX1 polymorphism
is located in the coding region (exon 1) of the HMOX1
gene, while the other polymorphism is in the 50 ﬂanking
region of the HMOX2 gene. We chose polymorphisms with
a minor allele frequency C3% in an European population.
The 19G[C-HMOX1 polymorphism is a non-synonymous
mutation resulting in an Asp to His substitution in the 7
codon. Non-synonymous coding polymorphisms along
with the polymorphism in the regulatory region of a gene
are believed to comprise a group of single nucleotide
polymorphisms (SNPs) that may the highest potential
phenotypic inﬂuence [27].
Materials and methods
Study subjects and data collection
Blood samples were obtained from 279 patients with AMD
and from 105 individuals without visual disturbances.
Among AMD patients, 101 had dry AMD and the
remaining 178—wet form of this disease. The character-
istics of patients and controls enrolled in this study are
presented in Supplementary Table 1. All patients and
controls were examined in the Department of Ophthal-
mology, Medical University of Warsaw (Warsaw, Poland).
They underwent ophthalmic examination, including best-
corrected visual acuity, intraocular pressure, slit lamp
examination, and fundus examination, performed with a
slit lamp equipped with either non-contact or contact fun-
dus lenses. Diagnosis of AMD was conﬁrmed by optical
coherence tomography (OCT) and, in some cases, by
ﬂuorescein angiography (FA) and indocyanin green angi-
ography (ICG). OCT evaluated retinal thickness, the
presence of RPE atrophy, drusen, or subretinal ﬂuid and
intraretinal edema; angiography assessed the anatomical
status of the retinal vessels, the presence of choroidal
neovascularization and leakage. The OCT examinations
were performed with Stratus OCT model 3000, software
version 4.0 (Oberkochen, Germany). The FA and ICG
examinations were performed with a Topcon TRC-50I IX
fundus camera equipped with the digital Image Net image
system, version 2.14 (Topcon, Tokyo, Japan). The study
design was approved by the Bioethics Committee of the
Medical University of Warsaw and each subject gave a
written informed consent. Each subject was interviewed to
provide data on tobacco smoking (never/ever), alcohol use
(never/ever) and other risk factors: sex, negative and
positive family history for AMD, age, living environment
(rural or urban areas). Each subject donated a 5 ml volume
venous blood sample, 250 ll of which was used for the
extraction of genomic DNA. All samples were coded after
collection of blood and completing the questionnaire.
Selection of SNPs for HMOX1 and HMOX2
and primer design
A list of SNPs in the HMOX1 and HMOX2 genes was
obtained from the public domain of the National Center for
Biotechnology Information at http://www.ncbi.nlm.nih.
gov/snp. We chose SNPs with a minor allele frequency
not lesser than 3% in the European population. Primers
were designed using the HMOX1 and HMOX2 genomic
sequence found at http://www.ensembl.org/Homo_sapiens/
Gene/Sequence?g=ENSG00000100292;r=22:35776354-35
790207 and http://www.ensembl.org/Homo_sapiens/Gene/
Sequence?g=ENSG00000103415;r=16:4524719-4560348)
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nl/cgi-bin/primer3plus/primer3plus.cgi).
DNA extraction and storage
Genomic DNA was prepared by using the commercial
AxyPrep
TM Blood Genomic DNA Miniprep Kit (Axygen
Biosciences, Union City, CA, USA), according to the
manufacturer’s instructions. DNA purity and concentra-
tions were determined spectrophotometrically at 260 and
280 nm. The puriﬁed genomic DNA was stored in TE
buffer (5 mM Tris–HCl, 0.1 mM EDTA, pH 8.5), at
-20C until use.
Genotyping
The genotypes of the 19 G[C-HMOX1 polymorphism
were determined by the allele-speciﬁc oligonucleotide-
PCR method. PCR assay was performed in a total volume
of 25 ll containing 50 ng of genomic DNA, 1 U Biotools
DNA polymerase (Biotools, Madrid, Spain), 19 reaction
buffer (750 mM Tris–HCl, pH 9.0, 500 mM KCl, 200 mM
(NH4)2SO4), 0.2 mM of each dNTP, 1.5 mM MgCl2,
0.25 lM of each primers (Metabion, Martinsried, Ger-
many). Thermal cycling conditions were as follows: initial
denaturation step at 95C for 5 min, 35 cycles at 95C for
30 s, 60 s at 63C annealing temperature and 60 s at 72C.
The ﬁnal extension step was performed for 7 min at 72C.
The following primers were used: allele-speciﬁc sense
oligonucleotides: 50-GGATGGAGCGTCCGCAACCCC-30
for C variant and 50-GGATGGAGCGTCCGCAACCCG-30
for G variant and antisense oligonucleotide: 50-CGCATA
CCAGGGTGCCAGGCAT-30. The PCR products (241 bp)
were run onto a 3% agarose gel, stained with ethidium
bromide and viewed under UV light. Supplementary Fig. 1
presents a representative gel for analysis of this
polymorphism.
The polymerase chain reaction-restriction fragment
length polymorphism (PCR–RFLP) method was used to
determine the genotypes of the -42 ? 1444A[G-HMOX2
polymorphism. PCR assay was performed in a total reac-
tion volume of 25 ll containing the same chemicals as in
the previous analysis except for primers. 385-bp length
fragments containing polymorphic site were ampliﬁed
using the following primers: sense 50-GGTGGTGCCAC
GGTTGACAA-30 and antisense 50-GTCCGCCAGCCTC
CAGTCAG-30. The PCR proﬁle contained an initial
denaturation step for 5 min at 95C, 30 cycles at 95C for
30 s, 30 s at 65C annealing temperature and 60 s at 72C
and the ﬁnal extension step for 5 min at 72C. After
ampliﬁcation, the 385-bp PCR products were analyzed in a
3% agarose gel and digested with 1 ll of FastDigest NlaIII
(Hin1II) restriction endonuclease (Fermentas, Hanover,
MD, USA) in a ﬁnal volume of 15 ll for 5 min at 37C.
PCR products with a G at the polymorphic site were
digested into two fragments of 211 and 174 bp, while those
with an A at this site were not cleaved because of the
absence of a NlaIII restriction site. The G/G genotype
produced two fragments (211 and 174 bp), whereas the
G/A genotype produced three fragments (385, 211, 174 bp)
and the homozygote A/A resulted in one fragment of
385 bp. Digested PCR products were separated by elec-
trophoresis on a 8% polyacrylamide gel and visualized by
ethidium bromide staining using a GeneRuler
TM 100 bp
(Fermentas, Hanover, MD, USA) as a size marker. A
representative gel for this polymorphism is presented in
Supplementary Fig. 2.
All PCR ampliﬁcations were conducted in a C1000
Thermal Cycler (Bio-Rad Laboratories, Hercules, CA,
USA). All experiments included positive and negative
controls for each polymorphism. We randomly selected
10% of 383 samples for repeated assays and the results
were 100% concordant.
Statistical analysis
All statistical analyses were performed using STATISTI-
CA 9.0 software (Statsoft, Tulsa, OK, USA) and SigmaPlot
v11.0 software (Systat Software, Inc., San Jose, CA, USA).
To compare the distributions of demographic variables and
selected risk factors between patients and controls v
2 test
was used. Hardy–Weinberg equilibrium was checked using
v
2 test to compare the observed genotype frequencies with
the expected frequencies among the case and control sub-
jects. The v
2 analysis was also used to test the signiﬁcance
of the differences between distributions of genotypes and
alleles in AMD patients and controls. The association
between case–control status and each polymorphism,
measured by the odds ratio (OR) and its corresponding
95% conﬁdence interval (CI), was estimated using an
unconditional multiple logistic regression model, both with
and without adjustment for sex, age, smoking habit, living
environment (rural vs. urban areas) and family status of
AMD. Tobacco smoking habit was categorized in terms of
never smokers and smokers, including current and former
smokers. Stratiﬁed analysis according to age, sex and
family status of AMD was also conducted. To study a
possible gene–environment interaction, the patients and
controls were divided into subgroups depending on sex,
family history and age. Unconditional logistic regression
analyses were also performed to assess the association
between genotypes and risk for AMD after stratiﬁcation of
the individuals according to sex, age and family status of
AMD.
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The PCR–RFLP and ASO-PCR analyses were successful
for all controls, but we were not able to determine the
genotypes of both polymorphisms for seven AMD patients.
Characteristics of the study population
The characteristic of the patients and controls is presented
in Supplementary Table 1. For six AMD patients we had
not information about sex and age. There were signiﬁcantly
more subjects with negative family history for AMD
among the controls than patients (96% vs. 80%,
P\0.001). Therefore, these variables were further adjus-
ted for in the multivariate logistic regression model to
control for possible confounding of the main effects of the
polymorphisms.
Relationship between age, sex, tobacco smoking, living
environment and AMD in family and the risk of AMD
independent of genotype
We investigated relationship between age, sex, smoking,
living environment and family history of AMD and the risk
of AMD independently of genotype. We compared controls
and AMD patients according to these parameters (Sup-
plementary Table 2). Male sex (OR 1.78, 95% CI
1.05–3.02; P = 0.031), age (7.77, 95% CI 2.73–22.12;
P\0.001) and family history of AMD (OR 6.80, 95% CI
2.02–22.90; P = 0.002) signiﬁcantly increased the risk of
AMD.
Polymorphisms of the HMOX-1 and -2 genes
and the risk of AMD
The genotype and allele distributions of the 19G[C-
HMOX1 and -42 ? 1444A[G-HMOX2 polymorphisms in
AMD patients and controls are summarized in Supple-
mentary Table 3. The genotype frequencies were all in
agreement with the Hardy–Weinberg equilibrium calcu-
lated for the cases and controls (P[0.05, data not show).
As shown in Supplementary Table 3 the difference in the
frequency distributions of genotypes between the cases of
dry AMD and controls was statistically signiﬁcant
(P\0.05). A weak association between dry AMD occur-
rence and the G/A genotype of the -42 ? 1444A[
G-HMOX2 polymorphism was found, whereas the homo-
zygous variant G/G was associated with a signiﬁcant
reduction in dry AMD risk. Moreover, the A allele of this
polymorphism was positively correlated with the occur-
rence of dry AMD, whereas the G allele had a protective
effect against dry AMD. We did not observe any
association between the occurrence of AMD its dry or wet
form and genotypes/alleles of the other polymorphism.
Additionally, we studied the distribution of genotypes
and alleles of the polymorphisms in the group of wet AMD
patients in comparison with dry AMD patients (Supple-
mentary Table 4). Such comparison was considered as a
measure of AMD progression. The G/C genotype and the C
of the 19G[C-HMOX1 polymorphism and the G/G geno-
type and the G allele of the -42 ? 1444A[G-HMOX2
polymorphism increased progression of AMD. Further-
more, the G/G genotype and the G allele of the 19G[C-
HMOX1 polymorphism and the G/A genotype and the A
allele of the HMOX2 SNP may have a protective effect
against disease progression.
Gene–gene interaction and AMD occurrence
and progression
We also assessed the association between the occurrence
and progression of AMD and combined genotypes of the
19G[C-HMOX1 and -42 ? 1444A[G-HMOX2 poly-
morphisms. The distribution of combined genotypes of
these polymorphisms are shown in Supplementary
Tables 5 and 6. The presence of the combined G/G–G/A
genotype increased the risk of dry AMD, while the pres-
ence of the G/G–G/G genotype decreased such risk.
Gene–gene interaction resulted in a slight increase in the
AMD progression from dry to wet form with the combined
G/G–G/G genotype, whereas the G/G genotype of the
19G[C-HMOX1 polymorphism and the A/G genotype of
the 42 ? 1444A[G-HMOX2 polymorphism were associ-
ated with a protective effect against progression of the
disease.
Gene–environment interaction and AMD occurrence
and progression
The association between AMD and the 19G[C-HMOX1
and the -42 ? 1444A[G-HMOX2 polymorphism was
subjected to stratiﬁcation analysis, but only data for the
-42 ? 1444A[G-HMOX2 are presented in Supplemen-
tary Table 7 because such analysis for other polymorphism
did not yield any signiﬁcant result. In stratiﬁcation analy-
sis, the G/G genotype was associated with a signiﬁcantly
decreased risk of AMD in subgroups of subjects of
61 years and older, women and subjects with no AMD
history in family. Moreover, the G/A genotype was asso-
ciated with a signiﬁcantly increased risk of AMD in sub-
groups of patients older than 61 years, women and subjects
with a negative family history for AMD.
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AMD is the leading cause of irreversible blindness in the
elderly in developed countries. As the elderly population
grows, age-related diseases, including AMD, become more
prevalent [28]. Approximately 25–30 million people
globally are affected by AMD and this number is expected
to triple over the next 25 years. The development of AMD
is a gradual process. Its progression occurs over an
extended time frame, with the incidence of the disease
increasing dramatically above 70 years old. Aging is
associated with changes in the retina, including alterations
in RPE cellular size and shape, thickening of BM, thick-
ening of the internal limiting membrane and a decrease in
retinal neuronal elements [29]. Generally, two types of
AMD can be considered: dry and wet [30], wherein dry
AMD accounts for 80–90% and wet AMD for 10–20% of
all cases. The majority of vision loss (*90%) is attributed
to wet AMD, which is the last and most severe phase of
macular degeneration progress [31]. The relationship
between dry and wet forms of AMD is not deﬁnite and dry
AMD may or may not eventually develop into the wet
form. It is estimated that dry form progresses to the wet
form in approximately 10% of cases. Therefore, our atti-
tude comparing the percentage of wet and dry cases as a
marker of the progression of AMD is limited.
Although the etiology and pathogenesis of AMD remain
largely unclear, a several genetic factors in combination
with environmental and lifestyle factors may be involved in
them. Results of several studies have shown that the most
recognized factors are advanced age, cigarette smoking,
race and diet [8, 9]. In the ﬁrst stage of our study, we
examined the relationship between clinical, environmental
and life style parameters and risk of AMD independently of
genotype. Our ﬁndings suggest that age, sex and family
status of AMD are risk factors in the development of the
disease. This is in general agreement with results obtained
by others [11, 32]. However, we did not ﬁnd any associa-
tion between tobacco smoking and AMD. At present we
have not any direct explanation of this fact except that
tobacco smoking may be one of the factor of AMD path-
ogenesis and not the sole reason of AMD and the role of
this factor depends on the population. Therefore, more
detailed characteristics of the population enrolled in the
present study might clear this issue.
Mitochondria belong to the major sources of ROS in
human lens epithelial cells. A growing body of evidence
suggests that mitochondria have a central role in age-
related disorders, including retinal diseases. Mitochondria-
associated diseases are recognized as a variety of many
important clinical entities that develop as a consequence of
abnormalities in energy supply, generators of ROS and
initiators of apoptotic processes [33].
During the aging, the balance between the generation
and clearance of ROS can be disturbed resulting in an
oxidative damage to outer segments of photoreceptors and
progressive deterioration of the RPE [34]. Several enzymes
are important in the formation and reduction of ROS. The
HO-1 and HO-2 may have an important role in diseases
that involve oxidative stress, including AMD. Frank et al.
[20] observed reduction in both HO-1 and HO-2 protein in
old age and in RPE cells from eyes with evidence of
neovascular AMD. Likewise, Miyamura et al. [35] found
an age-related decline in HO-1 mRNA expression in the
macula and the periphery of human subjects. Interestingly,
an overexpression of HO-1 in photoreceptors protected
them from subsequent cellular damage caused by an
intense light exposure [36].
In general, the role of genetic variability in AMD has
been extensively studied. Numerous case–control studies
have conﬁrmed the association between SNPs and AMD
[21–26]. Recent studies also report a signiﬁcant association
between the genetic polymorphism of genes encoding
antioxidant enzymes and development of AMD [37, 38].
Polymorphisms in the HMOX1 and HMOX2 genes have not
been studied in AMD patients so far. The human HMOX-1
gene is located at 22q12 and consists of ﬁve exons span-
ning *14 kb separated by four introns [39, 40]. We ana-
lyzed a G to C transversion located at the ?19 cDNA
position in the ﬁrst exon of the HMOX-1 gene. This
polymorphism causes change of aspartic acid to histidine at
the amino acid position 7 of the HO-1 protein, but the
clinical role of this change is unknown. A non-synonymous
SNP site with a low gene diversity, relative to other SNP
sites in the same gene that do not cause amino acid chan-
ges, might constitute a good candidate allele for disease
association [41]. Such substitution may directly affect the
structure and stability of protein with a serious phenotypic
consequences [42, 43]. We found that the occurrence of the
G/C genotype and the C allele of the c.19G[C polymor-
phism of the HMOX1 gene increased the progression of
AMD. Other studies showed that this SNP was not asso-
ciated with Alzheimer’s disease in Japanese population and
Parkinson’s disease in German population [44, 45]. The
other polymorphism, -42 ? 1444A[G-HMOX2, is loca-
ted in the 50 ﬂanking region of the gene, consisting of ﬁve
exons spanning *12 kb [39, 40]. HO-1 (32 kDa) and HO-
2 (36 kDa) share roughly 40% amino acid homology [46].
In summary, our results suggest that the 19G[C poly-
morphism of the HMOX1 gene and the -42 ? 1444A[G
polymorphism of the HMOX2 gene may be associated with
individual susceptibility to AMD. The identiﬁcation of
SNPs that are associated with variation in gene expression
in the retina and in the eye in general might help to identify
speciﬁc molecular signatures of AMD and ultimately help
to improve quality of life of AMD patients.
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Inconclusion,ourﬁndingssuggestthatthe 19G[C-HMOX1
polymorphism and the -42 ? 1444A[G-HMOX2 poly-
morphism may be linked with the development of AMD.
Acknowledgments This study was supported by the grant number
N N402 248336 of Ministry of Science and Higher Education.
Conﬂict of interest statement The authors declare that there are no
conﬂicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. World Health Organization (WHO) (2009) Priority eye diseases.
http://www.who.int/blindness/causes/priority/en/index8.html.
Accessed 20 Oct 2009
2. Gehrs KM, Anderson DH, Johnson LV, Hageman GS (2006)
Age-related macular degeneration-emerging pathogenetic and
therapeutic concepts. Ann Med 38:450–471
3. Fine SL, Berger JW, Maguire MG, Ho AC (2000) Age-related
macular degeneration. N Engl J Med 342:483–492
4. Stone EM, Shefﬁeld VC, Hageman GS (2001) Molecular genetics
of age-related macular degeneration. Hum Mol Genet 10:2285–
2292
5. Chen Y, Bedell M, Zhang K (2010) Age-related macular
degeneration: genetic and environmental factors of disease. Mol
Interv 10:271–281
6. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL III
(2005) Age-Related Eye Disease Study Research Group. Risk
factors for the incidence of Advanced Age-Related Macular
Degeneration in the Age-Related Eye Disease Study (AREDS)
AREDS report no. 19. Ophthalmology 112:533–539
7. van Newkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR,
McCarty CA (2000) The prevalence of age-related maculopathy:
the visual impairment project. Ophthalmology 107:1593–1600
8. Coleman HR, Chan CC, Ferris FL III, Chew EY (2008) Age-
related macular degeneration. Lancet 372:1835–1845
9. Jager RD, Mieler WF, Miller JW (2008) Age-related macular
degeneration. N Engl J Med 358:2606–2617
10. Meyers SM (1994) A twin study on age-related macular degen-
eration. Trans Am Ophthalmol Soc 92:775–843
11. Smith W, Mitchell P (1998) Family history and age-related
maculopathy: the Blue Mountains Eye Study. Aust NZ J Oph-
thalmol 26:203–206
12. Hyman L, Neborsky R (2002) Risk factors for age-related mac-
ular degeneration: an update. Curr Opin Ophthalmol 13:171–175
13. Klein ML, Francis PJ (2003) Genetics of age-related macular
degeneration. Ophthalmol Clin N Am 16:567–574
14. Seddon JM, Santangelo SL, Book K, Chong S, Cote J (2003) A
genome wide scan for age-related macular degeneration provides
evidence for linkage to several chromosomal regions. Am J Hum
Genet 73:780–790
15. Scholl HP, Fleckenstein M, Charbel Issa P, Keilhauer C, Holz
FG, Weber BH (2007) An update on the genetics of age-related
macular degeneration. Mol Vis 13:196–205
16. Welch KD, Davis TZ, Van Eden ME, Aust SD (2002) Deleterious
iron-mediated oxidation of biomolecules. Free Radic Biol Med
32:577–583
17. Reddy MB, Clark L (2004) Iron, oxidative stress, and disease
risk. Nutr Rev 62:120–124
18. Wong RW, Richa DC, Hahn P, Green WR, Dunaief JL (2007)
Iron toxicity as a potential factor in AMD. Retina 27:997–1003
19. Hahn P, Ying GS, Beard J, Dunaief JL (2006) Iron levels in
human retina: sex difference and increase with age. Neuroreport
17:1803–1806
20. Frank RN, Amin RH, Puklin JE (1999) Antioxidant enzymes in
the macular retinal pigment epithelium of eyes with neovascular
age-related macular degeneration. Am J Ophthalmol 127:
694–709
21. Patel N, Adewoyin T, Chong NV (2008) Age-related macular
degeneration: a perspective on genetic studies. Eye (Lond)
22:768–776
22. Janik-Papis K, Zaras M, Krzyzanowska A, Wozniak K, Blasiak J,
Szaﬂik J, Szaﬂik JP (2009) Association between vascular endo-
thelial growth factor gene polymorphisms and age-related mac-
ular degeneration in a Polish population. Exp Mol Pathol
87:234–238
23. Ding X, Patel M, Chan CC (2009) Molecular pathology of age-
related macular degeneration. Prog Retin Eye Res 28(1):1–18
24. Galan A, Ferlin A, Caretti L, Buson G, Sato G, Frigo AC, Foresta
C (2010) Association of age-related macular degeneration with
polymorphisms in vascular endothelial growth factor and its
receptor. Ophthalmology 117:1769–1774
25. Mori K, Horie-Inoue K, Gehlbach PL, Takita H, Kabasawa S,
Kawasaki I, Ohkubo T, Kurihara S, Iizuka H, Miyashita Y, Ka-
tayama S, Awata T, Yoneya S, Inoue S (2010) Phenotype and
genotype characteristics of age-related macular degeneration in a
Japanese population. Ophthalmology 117:928–938
26. Kopplin LJ, Igo RP Jr, Wang Y, Sivakumaran TA, Hagstrom SA,
Peachey NS, Francis PJ, Klein ML, Sangiovanni JP, Chew EY,
Pauer GJ, Sturgill GM, Joshi T, Tian L, Xi Q, Henning AK, Lee
KE, Klein R, Klein BE, Iyengar SK (2010) Genome-wide asso-
ciation identiﬁes SKIV2L and MYRIP as protective factors for
age-related macular degeneration. Genes Immun 11:609–621
27. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous
SNPs: server and survey. Nucleic Acids Res 30:3894–3900
28. Centers for Disease Control and Prevention (CDC) (2009) Why is
vision loss a public health problem? http://www.cdc.gov/
visionhealth/basic_information/vision_loss.htm. Accessed 20
Oct 2009
29. Green WR (1996) Retina: growth and aging. In: Spenser WH (ed)
Ophthalmic pathology, 4th edn. WB Saunders, Philadelphia,
pp 676–681
30. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV,
Anderson DH, Mullins RF (2001) An integrated hypothesis that
considers drusen as biomarkers of immune-mediated processes at
the RPE-Bruch’s membrane interface in aging and age-related
macular degeneration. Prog Retin Eye Res 20:705–732
31. Bressler NM (2002) Early detection and treatment of neovascular
age-related macular degeneration. J Am Board Fam Pract
15:142–152
32. Geirsdottir A, Stefansson E, Jonasson F, Helgadottir G, Sig-
urdsson H (2007) Age-related macular degeneration in very old
individuals with family history. Am J Ophthalmol 143:889–890
33. Qi S, Wang Y, Zhou M, Ge Y, Yan Y, Wang J, Zhang SS, Zhang
S (2011) A mitochondria-localized glutamic acid-rich protein
(MGARP/OSAP) is highly expressed in retina that exhibits a
large area of intrinsic disorder. Mol Biol Rep 38:2869–2877
34. Totan Y, Yag ˘ci R, Bardak Y, Ozyurt H, Kendir F, Yilmaz G,
Sahin S, Sahin Tig ˘ U (2009) Oxidative macromolecular damage
in age-related macular degeneration. Curr Eye Res 34:1089–1093
2086 Mol Biol Rep (2012) 39:2081–2087
12335. Miyamura N, Ogawa T, Boylan S, Morse LS, Handa JT,
Hjelmeland LM (2004) Topographic and age-dependent expres-
sion of heme oxygenase-1 and catalase in the human retinal
pigment epithelium. Investig Ophthalmol Vis Sci 45:1562–1565
36. Sun MH, Pang JH, Chen SL, Kuo PC, Chen KJ, Kao LY, Wu JY,
Lin KK, Tsao YP (2007) Photoreceptor protection against light
damage by AAV-mediated overexpression of heme oxygenase-1.
Investig Ophthalmol Vis Sci 48:5699–5707
37. Kimura K, Isashiki Y, Sonoda S, Kakiuchi-Matsumoto T, Ohba N
(2000) Genetic association of manganese superoxide dismutase
with exudative age-related macular degeneration. Am J Oph-
thalmol 130:769–773
38. Ayala-HaedoJA,GallinsPJ,WhiteheadPL,SchwartzSG,Kovach
JL,PostelEA,AgarwalA,WangG,HainesJL,Pericak-VanceMA,
Scott WK (2010) Analysis of single nucleotide polymorphisms in
the NOS2A gene and interaction with smoking in age-related
macular degeneration. Ann Hum Genet 74:195–201
39. Kutty RK, Kutty G, Rodriguez IR, Chader GJ, Wiggert B (1994)
Chromosomal localization of the human heme oxygenase genes:
heme oxygenase-1 (HMOX1) maps to chromosome 22q12 and
heme oxygenase-2 (HMOX2) maps to chromosome 16p13.3.
Genomics 20:513–516
40. Abraham NG, Drummond GS, Lutton JD, Kappas A (1996) The
biological signiﬁcance and physiological role of heme oxygenase.
Cell Physiol Biochem 6:129–168
41. Hughes AL, Packer B, Welch R, Bergen AW, Chanock SJ,
Yeager M (2003) Widespread purifying selection at polymorphic
sites in human protein-coding loci. Proc Natl Acad Sci USA
100:15754–15757
42. Ng PC, Henikoff S (2006) Predicting the effects of amino acid
substitutions on protein function. Annu Rev Genomics Hum
Genet 7:61–80
43. Lee PH, Shatkay H (2008) F-SNP: computationally predicted
functional SNPs for disease association studies. Nucleic Acids
Res 36:D820–D824
44. Funke C, Tomiuk J, Riess O, Berg D, Soehn AS (2009) Genetic
analysis of heme oxygenase-1 (HO-1) in German Parkinson’s
disease patients. J Neural Transm 116:853–859
45. Shibata N, Ohnuma T, Baba H, Arai H (2009) No genetic asso-
ciation between polymorphisms of heme oxygenase 1 and 2 and
Alzheimer’s disease in a Japanese population. Dement Geriatr
Cogn Disord 27:273–277
46. Maines MD (1997) The heme oxygenase system: a regulator of
secondmessengergases.AnnuRevPharmacolToxicol 37:517–554
Mol Biol Rep (2012) 39:2081–2087 2087
123